TY - JOUR
T1 - EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease
AU - Levy, Antonin
AU - Hendriks, Lizza E. L.
AU - Berghmans, Thierry
AU - Faivre-Finn, Corinne
AU - GiajLevra, Matteo
AU - GiajLevra, Niccolo
AU - Hasan, Baktiar
AU - Pochesci, Alessia
AU - Girard, Nicolas
AU - Greillier, Laurent
AU - Lantuejoul, Sylvie
AU - Edwards, John
AU - O'Brien, Mary
AU - Reck, Martin
AU - Besse, Benjamin
AU - Novello, Silvia
AU - Dingemans, Anne-Marie C.
AU - EORTC Lung Cancer Group
N1 - Funding Information:
This publication was supported by a donation from the “La Ligue Nationale Contre le Cancer” from France through the EORTC Cancer Research Fund.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/11
Y1 - 2019/11
N2 - Background: Synchronous oligometastatic disease (sOM) has been described as a distinct disease entity; however, there is no consensus on OM definition (OM-d) in non esmall-cell lung cancer (NSCLC). A consensus group was formed aiming to agree on a common OM-d that could be used in future clinical trials. A European survey was circulated to generate questions and input for the consensus group meeting.Methods: A European Organisation for Research and Treatment of Cancer Lung Cancer Group (LCG)/sOM-d consensus group survey was distributed to LCG, sOM-d consensus group, and several European thoracic oncology societies' members.Results: 444 responses were analysed (radiation oncologist: 55% [n = 242], pulmonologist: 15% [n = 66], medical oncologist: 14% [n = 64]). 361 physicians (81%) aimed to cure sOM NSCLC patients and 82% (n=362) included the possibility of radical intent treatment in their sOM-d. The maximum number of metastases considered in sOM-d varied: 12% replied 1 metastasis, 42% = 5 metastases. 79% (n = 353) stated that number of organs involved was important for sOM-d, and most (80%, n = 355) considered that onlyConclusion: Although consensual answers were obtained, several issues remain unresolved and will require further research to agree on a sOM-d. (C) 2019 Elsevier Ltd. All rights reserved.
AB - Background: Synchronous oligometastatic disease (sOM) has been described as a distinct disease entity; however, there is no consensus on OM definition (OM-d) in non esmall-cell lung cancer (NSCLC). A consensus group was formed aiming to agree on a common OM-d that could be used in future clinical trials. A European survey was circulated to generate questions and input for the consensus group meeting.Methods: A European Organisation for Research and Treatment of Cancer Lung Cancer Group (LCG)/sOM-d consensus group survey was distributed to LCG, sOM-d consensus group, and several European thoracic oncology societies' members.Results: 444 responses were analysed (radiation oncologist: 55% [n = 242], pulmonologist: 15% [n = 66], medical oncologist: 14% [n = 64]). 361 physicians (81%) aimed to cure sOM NSCLC patients and 82% (n=362) included the possibility of radical intent treatment in their sOM-d. The maximum number of metastases considered in sOM-d varied: 12% replied 1 metastasis, 42% = 5 metastases. 79% (n = 353) stated that number of organs involved was important for sOM-d, and most (80%, n = 355) considered that onlyConclusion: Although consensual answers were obtained, several issues remain unresolved and will require further research to agree on a sOM-d. (C) 2019 Elsevier Ltd. All rights reserved.
KW - Oligometastasis
KW - Non-small cell lung cancer
KW - Consensus
KW - STEREOTACTIC BODY RADIOTHERAPY
KW - EUROPEAN ORGANIZATION
KW - PHASE-II
KW - THERAPY
KW - TRIAL
U2 - 10.1016/j.ejca.2019.09.012
DO - 10.1016/j.ejca.2019.09.012
M3 - Article
C2 - 31671363
SN - 0959-8049
VL - 122
SP - 109
EP - 114
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -